lobbying_activities: 2780576

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2780576	2b8f61a1-9b5e-4211-8178-36e823d10197	Q1	MCDERMOTT+ LLC	401103287	CAMPAIGN FOR SUSTAINABLE DRUG PRICING	2022	first_quarter	PHA	S. 1391 - Fair Accountability and Innovative Research Drug Pricing Act. Prescription drug pricing issues. Patent abuse issues. Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021. Drug-price Transparency for Competition (DTC) Act. H.R. 5376 - Build Back Better Act. Prescription Drug User Fee Act. H.R. 6833 - Affordable Insulin Now Act. National Coverage Determination on Aduhelm.	Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office	30000		0	0	2022-04-18T17:44:00-04:00